

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>NOMURA INTERNATIONAL PLC</u> <hr/> (Last) (First) (Middle) NOMURA HOUSE 1 ST MARTIN'S-LE-GRAND <hr/> (Street) LONDON X0 EC1A 4NP <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/18/2005	3. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC [ ACAD ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) Member of 13G Group (1)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$0.0001 per share ("Common Stock")	2,199,010	I	Notes <sup>(1)(2)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Warrant to purchase Common Stock	10/17/2005	04/20/2010	Common Stock Amount or Number of Shares: 549,752	8.15	I	Notes <sup>(1)(2)</sup>

1. Name and Address of Reporting Person\*  
NOMURA INTERNATIONAL PLC  


---

 (Last) (First) (Middle)  
 NOMURA HOUSE  
 1 ST MARTIN'S-LE-GRAND  


---

 (Street)  
 LONDON X0 EC1A 4NP  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Nomura Phase4 Ventures LTD  


---

 (Last) (First) (Middle)  
 NOMURA HOUSE  
 1 ST MARTIN'S-LE-GRAND  


---

 (Street)  
 LONDON X0 EC1A 4NP  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Nomura Phase4 Ventures GP LTD  


---

 (Last) (First) (Middle)  
 NOMURA HOUSE  
 1 ST MARTIN'S-LE-GRAND  


---

 (Street)  
 LONDON X0 EC1A 4NP  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Nomura Phase4 Ventures LP  


---

 (Last) (First) (Middle)  
 NOMURA HOUSE  
 1 ST MARTIN'S-LE-GRAND  


---

 (Street)  
 LONDON X0 EC1A 4NP  


---

 (City) (State) (Zip)

**Explanation of Responses:**

1. See Exhibit 99.1 for the identities of each Reporting Person and for a table of all shares beneficially owned directly or indirectly by each of the Reporting Persons.
2. Directly owned by Nomura Phase4 Ventures L.P.

[See Exhibit 99.1 for signature information.](#)

[08/23/2005](#)

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

## NAME AND ADDRESS OF REPORTING PERSON:

Nomura International plc  
 Nomura House  
 1 St Martins-le-Grand  
 London, EC1A 4NP  
 United Kingdom

## ISSUER NAME AND TICKER OR TRADING SYMBOL:

Acadia Pharmaceuticals, Inc. (the "Issuer")

## DATE OF EARLIEST TRANSACTION REQUIRED TO BE REPORTED:

August 18, 2005 (date upon which 10% threshold was surpassed),  
 April 20, 2005 (date upon which common stock and warrants were purchased)

## Explanation of Responses:

-----

This Form 3 is filed by Nomura International plc ("NI") on behalf of Nomura Phase4 Ventures LP ("NLP"), Nomura Phase4 GP Limited ("NGP") and Nomura Phase4 Ventures Limited ("NVL") (each a "Reporting Person"). Each Reporting Person is a member of a 13G Group reporting more than 10% ownership of the Common Stock of the Issuer.

Reporting Person -----	Amount of Securities Beneficially Owned Following Reported Transaction(s) -----	Ownership Form: Direct (D) or Indirect (I) -----	Nature of Indirect Beneficial Ownership -----
Nomura International plc	2,748,762	I	
Nomura Phase4 Ventures Limited	2,748,762	I	(1)
Nomura Phase4 GP Limited	2,748,762	I	(2)
Nomura Phase4 Ventures LP	2,748,762	D	(3)

NI owns directly all of the stock of NVL. NVL owns directly all of the stock of NGP. NGP is the manager of NLP. NLP acquired 2,199,010 shares of Common Stock of the Issuer pursuant to that certain Securities Purchase Agreement dated April 15, 2005 by and among the Issuer and certain purchasers listed therein. As part of the same transaction, NLP received a warrant, exercisable commencing on October 17, 2005, to purchase an additional 549,752 shares of Common Stock of the Issuer.

Each Reporting Person disclaims beneficial ownership of all indirectly owned securities reported on this Form in excess of such Reporting Person's pecuniary interest therein.

## JOINT FILER INFORMATION

NAME: Nomura Phase4 Ventures Limited

ADDRESS:  
 Nomura House  
 1 St Martins-le-Grand  
 London, EC1A 4NP  
 United Kingdom

ISSUER AND TICKER SYMBOL: Acadia Pharmaceuticals, Inc.

DATE OF EARLIEST TRANSACTION REQUIRED TO BE REPORTED: April 20, 2005

RELATIONSHIP OF REPORTING PERSONS TO ISSUER: Member of 13G Group reporting more than 10% ownership.

SIGNATURE: Nomura Phase4 Ventures Limited

By: /s/ Denise Pollard-Knight  
 -----

Dated: August 23, 2005

JOINT FILER INFORMATION

NAME: Nomura Phase4 Ventures GP Limited

ADDRESS:  
Nomura House  
1 St Martins-le-Grand  
London, EC1A 4NP  
United Kingdom

ISSUER AND TICKER SYMBOL: Acadia Pharmaceuticals, Inc.

DATE OF EARLIEST TRANSACTION REQUIRED TO BE REPORTED: April 20, 2005

RELATIONSHIP OF REPORTING PERSONS TO ISSUER: Member of 13G Group reporting  
more than 10% ownership.

SIGNATURE: Nomura Phase4 Ventures GP Limited

By: /s/ Denise Pollard-Knight  
-----

Dated: August 23, 2005

JOINT FILER INFORMATION

NAME: Nomura Phase4 Ventures LP

ADDRESS:  
Nomura House  
1 St Martins-le-Grand  
London, EC1A 4NP  
United Kingdom

ISSUER AND TICKER SYMBOL: Acadia Pharmaceuticals, Inc.

DATE OF EARLIEST TRANSACTION REQUIRED TO BE REPORTED: April 20, 2005

RELATIONSHIP OF REPORTING PERSONS TO ISSUER: Member of 13G Group reporting  
more than 10% ownership.

SIGNATURE: Nomura Phase4 Ventures LP

By: /s/ Denise Pollard-Knight  
-----

Dated: August 23, 2005